Pre-exposure Prophylaxis for SARS-Coronavirus-2
Clara Health

Pre-exposure Prophylaxis for SARS-Coronavirus-2

Sponsored by University of Minnesota


The current standard of care is observation and quarantine after exposure to COVID-19. There is no approved treatment or prophylaxis for COVID-19.

Chloroquine or Hydroxychloroquine may have antiviral effects against SARS-COV2 which may prevent COVID-19 disease or reduce disease severity. It is not known at what dosing hydroxychloroquine may be effective for pre-exposure prophylaxis.

About 
COVID-19

Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.

How is this study designed?

Study Type: Interventional (Clinical Trial) Estimated Enrollment: 3500 participants Primary Purpose: Treatment Actual Study Start Date: April 6, 2020 Estimated Study Completion Date: August 2020

Who is this study for?

Inclusion Criteria*: A healthcare worker at high risk for COVID-19 exposure (defined below):

  • Persons primarily working in emergency departments (physicians, nurses, ancillary staff, triage personnel)
  • Persons primarily working in intensive care units (physicians, nurses, ancillary staff, respiratory therapists)
  • Persons performing aerosol generating procedures (i.e. anesthesiologists, nurse anesthetists (CRNAs)
  • First responders (i.e. EMTs, paramedics)

Exclusion Criteria*:

  • Active COVID-19 disease
  • Prior COVID-19 disease
  • Current fever, cough, shortness of breath

* Additional criteria apply. Please speak with the study team for further information.

What should I expect?

Arm 1: Intervention Once Weekly 400 mg orally once, followed by 400mg 6 to 8 hours later, thereafter 400mg weekly for the duration of follow up, up to 12 weeks

Arm 2: Intervention Twice Weekly 400mg orally once, followed by 400mg 6 to 8 hours later, thereafter 400mg twice weekly for the duration of follow up, up to 12 weeks

Arm 3: Control Group Placebo 2 tabs once, followed by 2 tabs 6 to 8 hours later, thereafter two tabs weekly or twice weekly for the duration of follow up, up to 12 weeks

Participate in the Pre-exposure Prophylaxis for SARS-Coronavirus-2 study

Thank you for your interest in advancing COVID-19 research.

Please fill out this contact form to be connected to a member of the study team. The following information that you enter will only be authorized to be shared with the research team conducting this specific study.

If you have any difficulties or questions, please contact our support specialists at [email protected]

Have questions or need help?

For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you'll be connected to the team.